Showing results (291-300 of 760) with videos related to

Sort By:
Pageof 76
Oncology (Williston Park, N.Y.)|August 29, 2007
Novel therapeutic avenues in myeloma: changing the treatment paradigmJoanne Ghobrial, Irene M Ghobrial, Constantine Mitsiades, et al.
Cancer Research|September 17, 2005
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cellsDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Blood|April 14, 2005
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaNoopur Raje, Shaji Kumar, Teru Hideshima, et al.
Blood|December 10, 2013
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceZe Tian, Padraig D'Arcy, Xin Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2008
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaMasahisa Jinushi, Matthew Vanneman, Nikhil C Munshi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 21, 2003
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based reviewTheresa Hahn, John R Wingard, Kenneth C Anderson, et al.
Blood|May 27, 2006
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsLaurence Catley, Ellen Weisberg, Tanyel Kiziltepe, et al.
Blood|October 18, 2003
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigensRoberto Bellucci, Catherine J Wu, Sabina Chiaretti, et al.
The Journal of Biological Chemistry|March 2, 2002
NF-kappa B as a therapeutic target in multiple myelomaTeru Hideshima, Dharminder Chauhan, Paul Richardson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasiasConstantine S Mitsiades, Cecile Rouleau, Cinara Echart, et al.
Pageof 76